 |
|||
 |
 |
 |
|
PSMA Subunit Vaccine
We are concluding a phase 1 clinical trial with our therapeutic recombinant protein vaccine, a genetically engineered form of the PSMA protein combined with a potent immunological stimulant, is designed to stimulate a patient's immune system to recognize and destroy prostate cancer cells. The vaccine combines the PSMA cancer antigen (recombinant soluble PSMA, or "rsPSMA") with an immune stimulant to induce an immune response against prostate cancer cells. The genetically engineered PSMA vaccine generated potent immune responses in preclinical animal testing. Additional research will be needed to optimize the production, immune response and anti-tumor activity of the vaccine before this product candidate will advance to phase 2.